Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy
Decline in respiratory function in patients with DMD starts during early teenage years and leads to early morbidity and mortality. Published evidence of efficacy for idebenone on respiratory function outcomes is currently limited to 12 months of follow-up time. Here we report data collected as retro...
Главные авторы: | Servais, L, Straathof, CSM, Schara, U, Klein, A, Leinonen, M, Hasham, S, Meier, T, De Waele, L, Gordish-Dressman, H, McDonald, CM, Mayer, OH, Voit, T, Mercuri, E, Buyse, GM |
---|---|
Формат: | Journal article |
Язык: | English |
Опубликовано: |
Elsevier
2019
|
Схожие документы
-
Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
по: Theodora Markati, и др.
Опубликовано: (2021-11-01) -
Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy
по: Marshall W. Hogarth, и др.
Опубликовано: (2017-01-01) -
Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy
по: Fatima Amor, и др.
Опубликовано: (2021-06-01) -
Duchenne Muscular Dystrophy
по: J Gordon Millichap
Опубликовано: (1989-05-01) -
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
по: Frank, DE, и др.
Опубликовано: (2020)